Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound represented by formula

Formula 1

(1):

wherein

 R^1 , R^2 and R^5 are each independently selected from a hydrogen atom, a halogen atom, a C_1 - C_6 alkyl group which may be substituted with one or more halogen atoms and a C_1 - C_6 alkoxy group which may be substituted with one or more halogen atoms;

R₂ selected from the group consisting of halogen atom, a C₁-C₆ alkyl group which is substituent with one or more halogen atoms and a C₁-C₆ alkoxy group which is substituted with one or more halogen atoms:

 R^3 and R^4 are each independently selected from a hydrogen atom, a halogen atom, -NRfRg, -CONRfRg, -a C_1 - C_6 alkoxy group, a C_1 - C_6 alkyl group and -T- $(CH_2)_k$ -V, wherein the alkyl group and the alkoxy group may be substituted with one or more

substituents selected from a hydroxyl group, a

C₁-C₆ alkoxy group, a halogen atom and -NRfRg;

wherein

Re is selected from a hydrogen atom and C_1 - C_6 alkyl, wherein the alkyl group may be substituted with one to three substituents selected from a hydroxyl group, a C_1 - C_6 alkoxy group, a halogen atom and -NRhRi,

Rf and Rg are each independently selected from a hydrogen atom, C_1 - C_6 alkyl group and C_1 - C_6 alkylcarbonyl group, wherein the alkyl group and the alkylcarbonyl group may be substituted with one to three substituents selected from a hydroxyl group, a C_1 - C_6 alkoxy group, a halogen atom and

-NRhRi,

Rh and Ri are each independently selected from a hydrogen atom and C_1 - C_6 alkyl group, wherein the alkyl group may be substituted with one to three substituents selected from a hydroxyl group, a halogen atom and a C_1 - C_6 alkoxy group, or

Rf and Rg, and Rh and Ri together with a nitrogen atom to which they

are attached may form a 4- to

7-heterocycle, wherein the heterocycle may be substituted with a C_1 - C_6 alkyl group,

T is an oxygen atom or a single bond; k is an integer selected from 0 to 4;

V is a 5- to 6-membered heterocyclyl group which may be substituted with one or more substituents selected from the group consisting of -NRxRy,

-C(=0)Rz, -ORz and a C_1 - C_6 alkyl group, or V is -NRaRb, -CONRaRb,

-OC(=O)NRaRb, -SO2NRaRb, -N(-Ra)C(=O)NRa'Rb', -N(-Ra)C(=O)ORd,

-C(=O)ORd, $-S(=O)_m-Rd$, -O-Rd, -OC(=O)Rc, -N(-Ra)C(=O)Rc,

 $-N(Ra)SO_2Rc$, -C(=NRa)NRa'Rb', -C(=NORa)Rc or -C(=O)Rc;

R⁶ and R⁷ are each independently selected from a hydrogen atom and a halogen atom;

 Z^1 and Z^2 are each independently selected from a hydrogen atom, a hydroxyl group and -O(CHR¹¹)OC(=0)R¹²;

wherein

 R^{11} is a hydrogen atom or a C_1 - C_6 alkyl group;

 R^{12} is a pyrrolidinyl group, a piperidinyl group, a morpholinyl group, a piperazinyl group, an amino C_1 - C_6 alkyl group, a mono- or di(C_1 - C_6 alkyl) amino C_1 - C_6 alkyl group, an amino C_1 - C_6 alkylamino group or a mono- or di(C_1 - C_6 alkyl)-amino C_1 - C_6 alkylamino group;

Q is a group of

Formula 2

wherein

 Y^1 is selected from the group consisting of a hydrogen atom, a halogen atom, and a C_2 - C_6 alkenyl group;

Wherein

Q is optionally substituted by at least one substituents W, where W is -NRaRb,

-N=C(-Rc)NRaRb, -N(-Ra)C(=O)NRa'Rb'or -N(-Ra)C(=O)Rc;

Ra, Ra', Rb, Rb', Rc, and Rd are each independently selected from the group consisting of a hydrogen atom, a C_1 - C_{10} alkyl group, a C_3 - C_8 cycloalkyl group, a C_2 - C_8 alkenyl group, a C_2 - C_8 alkynyl group, -[(C_1 - C_6 alkylene)-O]_n-(C_1 - C_3 alkyl),

a tetrahydropyranyl group, a tetrahydrofuranyl group, an aryl group, a heteroaryl group, and a nitrogen-containing heterocyclyl group (wherein the nitrogen atom on the heterocyclyl group may be substituted with a C_1 - C_3 alkyl group);

Ra and Rb, Ra' and Rb', Ra and Rd, Ra and Ra', Ra and Rc, and Rd and Ra' may form a saturated or unsaturated 5- to 6-membered heterocycle by ring-closing at the bonding position of each of these two groups and the heterocycle may be substituted with a C₁-C₆ alkyl group;

Ra, Ra', Rb, Rb', Rc, and Rd each may be substituted with one to three same or different substituents selected from Y³;

m is an integer selected from 0 to 2;

n is an integer selected from 1 to 4;

 $Y^3 \text{ is a halogen atom, -NRxRy, -C(=0)ORz, -C(=0)Rz, -ORz, -C(=0)NRxRy, -OC(=0)NRxRy, -SO_2NRxRy, -N(-Rx)C(=0)NRx'Ry', -N(-Rx)C(=0)ORz, -S-Rz, -SO-Rz, -SO_2-Rz, -OC(=0)Rz, -N(Rx)C(=0)Rz, -C(=NORz)NRx'Ry', -C(=NRx)NRx'Ry', -C(=NORx)Rz, -[O-(C_1-C_6 alkylene)]_n-O(C_1-C_3 alkyl), -N(-Rx)-(C_1-C_6 alkylene)-O(C_1-C_3 alkyl), -C(=0)Rz, a C_1-C_6 alkylene, a C_2-C_8 alkenyl group, a C_2-C_8$

Rx, Rx', Ry, Ry' and Rz are each independently selected from a hydrogen atom and a C_1 - C_4 alkyl group;

alkynyl group, an aryl group or a heteroaryl group;

Rx and Ry, Rx and Rx', Rx and Rz, and Rz and Rx' may form a saturated or unsaturated 5-to 6-membered heterocycle by ring-closing at the bonding position of each of these two groups; a pharmaceutically acceptable salt thereof.

- 2. (Previously Presented) The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein R² is selected from a halogen atom, a trifluoromethyl group and a trifluoromethoxy group.
- 3. (Previously Presented) The compound of claim 2, a pharmaceutically acceptable salt thereof, wherein Q is a group of the formula selected from

Formula 3

which may be substituted with one to three same or different substituents W.

Claims 4-5. (Cancelled)

6. (Previously Presented) The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein

R¹, R², R³, R⁴ and R⁵ are each independently selected from a hydrogen atom, a chlorine atom, a fluorine atom, a bromine atom and a trifluoromethyl group;

R⁶ and R⁷ are hydrogen atoms; and

 Z^1 and Z^2 are each independently selected from a hydrogen atom, and a hydroxyl group.

7. (Previously Presented) The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein

 R^3 and R^4 are each independently selected from a hydrogen atom, a halogen atom, a C_1 - C_6 alkyl group which may be substituted with one or more hydroxyl groups or halogen atoms, a C_1 - C_6 alkoxy group which may be substituted with one or more halogen atoms, and -T- $(CH_2)_k$ -V;

T is an oxygen atom or a single bond; k is an integer selected from 0 to 4;

V is a 5- to 6-menbered heterocyclyl group which may be substituted with one or more substituents selected from a hydroxy group, an amino group, C₁-C₆ alkyl group, C₁-C₆ alkoxy group and C₁-C₆ alkylcarbonyl group.

- 8. (Previously Presented) A compound or a pharmaceutically acceptable salt thereof of claim 1 which has Raf inhibiting effect and angiogenesis inhibiting effect and is used for treating cancer, psoriasis, atherosclerosis, chronic rheumatoid arthritis and diabetes.
 - 9. (Previously Presented) A pharmaceutical composition

comprising a compound or a pharmaceutically acceptable salt thereof of claim 1 as an active ingredient.

- 10. (Previously Presented) An Raf inhibitor or an angiogenesis inhibitor comprising a compound or a pharmaceutically acceptable salt thereof of claim 1 as an active ingredient.
- 11. (Previously Presented) A therapeutic agent for a disease selected from cancer, psoriasis, atherosclerosis, chronic rheumatoid arthritis and diabetes which comprises a compound or a pharmaceutically acceptable salt thereof of claim 1 as an active ingredient.

Claims 12-13. (Cancelled)